View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

FDA Delays Publication of Generic CBE Rule Until Fall 2015

By Charles Jaap, MBA, RAC 

US Food and Drug Administration (FDA) have delayed publication of a rule proposed last year that would allow generic drug sponsors to update safety warnings using the CBE process.

While the comment period was extended, there was no corresponding extension in the scheduled publication date of December 2014. FDA received more than 100 comments concerning the measure.

When announcing the extension, the FDA spokeswoman said: "FDA received a great deal of public input from various stakeholders during the comment period on the proposed rule.

We are committed to reviewing and considering all of the comments received as we develop the final rule."

Pharmaceutical Development Group (PDG) will continue to update readers as events unfold.

Clinical trial consulting and pharmaceutical consulting professionals will benefit by becoming current on adaptive trial design.
Safety surveillance and pharmacovigilance consulting to generic drug manufacturers, as well as generic drug labelling consulting may soon become a service in demand.
Pharmaceutical Development Group (PDG) is a drug and medical device consultant that continuously engages in meetings and interactions with the US Food and Drug Administration...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology